CoChat
Sign Up
Cited by 61

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence: Mast Cells and Prostate Cancer Recurrence

Hempel, Heidi A., Cuka, Nathan S., Kulac, Ibrahim, Barber, John R., Cornish, Toby C., Platz, Elizabeth A., De Marzo, Angelo M., Sfanos, Karen S.·2017·The Prostate
DOI 10.1002/pros.23280
Open this paper in CoChat — free account

Abstract

Background Mast cells are of interest in prostate cancer because they possess both pro- and anti-tumorigenic properties and are present in the tumor microenvironment. We studied the association of mast cell count and densities with prostate cancer recurrence using tissue microarrays (TMAs) for 462 men who recurred (cases) and 462 controls that were matched to the cases nested in a cohort of radical prostatectomy patients. Methods Dual-immunostaining for mast cell tryptase and epithelial cytokeratin-8 and whole slide image analysis were used to assess total mast cell number, mast cell density (mast cell number/tissue area), and mast cell number per epithelial or stromal area in TMA spots containing tumor (up to 4 per man). We used conditional logistic regression to estimate the odds ratio (OR) and 95% confidence interval of recurrence for the mean, minimum, and maximum mast cell parameters in tumor tissue among each man's TMA spots. Results After taking into account matching factors of age, race, Gleason sum, and pathologic stage, higher minimum mast cell density in the tumor (comparing highest to lowest quartiles: OR = 0.58, 95% CI 0.40-0.86; P-trend = 0.004) was associated with a lower risk of recurrence. Patterns for mast cell number and ratio of mast cell number to epithelial or stromal area were similar to those for mast cell density. Conclusions Our results suggest that intratumoral mast cells may be protective against prostate cancer recurrence and could potentially ser…

Overview

Integrity signals

Registry

Crossref · 10.1002/pros.23280

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 40

  1. Vendramini-Costa, 2012, Molecular link mechanisms between inflammation and cancer, Curr Pharm Des, 18, 3831, 10.2174/138161212802083707 · DOI
  2. Iijima, 2011, Inflammatory alterations of the extracellular matrix in the tumor microenvironment, Cancers, 3, 3189, 10.3390/cancers3033189 · DOI
  3. Theoharides, 2004, Mast cells: The JEKYLL and HYDE of tumor growth, Trends Immunol, 25, 235, 10.1016/j.it.2004.02.013 · DOI
  4. Sfanos, 2012, Prostate cancer and inflammation: The evidence, Histopathology, 60, 199, 10.1111/j.1365-2559.2011.04033.x · DOI
  5. De Marzo, 1999, Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis, Am J Pathol, 155, 1985, 10.1016/S0002-9440(10)65517-4 · DOI
  6. De Marzo, 2007, Inflammation in prostate carcinogenesis, Nat Rev Cancer, 7, 256, 10.1038/nrc2090 · DOI
  7. Platz, 2004, Epidemiology of inflammation and prostate cancer, J Urol, 171, S36, 10.1097/01.ju.0000108131.43160.77 · DOI
  8. Nelson, 2003, Prostate cancer, N Engl J Med, 349, 366, 10.1056/NEJMra021562 · DOI
  9. Ammirante, 2010, B cell-derived lymphotoxin promotes castration-resistant prostate cancer, Nature, 464, 302, 10.1038/nature08782 · DOI
  10. Chavin, 2009, Expression of immunosuppresive B7-H3 ligand by hormone-Treated prostate cancer tumors and metastases, Clin Cancer Res, 15, 2174, 10.1158/1078-0432.CCR-08-2262 · DOI
  11. Zang, 2007, B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome, Proc Natl Acad Sci USA, 104, 19458, 10.1073/pnas.0709802104 · DOI · Paper page
  12. Flammiger, 2012, Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer, APMIS, 120, 901, 10.1111/j.1600-0463.2012.02924.x · DOI
  13. Loberg, 2006, CCL2 is a potent regulator of prostate cancer cell migration and proliferation, Neoplasia (New York, NY), 8, 578, 10.1593/neo.06280 · DOI
  14. Mizutani, 2009, The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment, Neoplasia (New York, NY), 11, 1235, 10.1593/neo.09988 · DOI
  15. Lee, 1998, Alteration of protease expression phenotype of mouse peritoneal mast cells by changing the microenvironment as demonstrated by in situ hybridization histochemistry, Am J Pathol, 153, 931, 10.1016/S0002-9440(10)65634-9 · DOI
  16. Aggarwal, 2014, Inflammation and cancer, 816, 10.1007/978-3-0348-0837-8 · DOI
  17. Ellem, 2014, A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment, J Pathol, 234, 86, 10.1002/path.4386 · DOI
  18. Galinsky, 2008, Mast cells and cancer-No longer just basic science, Crit Rev Oncol Hematol, 68, 115, 10.1016/j.critrevonc.2008.06.001 · DOI
  19. Pittoni, 2012, The dark side of mast cell-targeted therapy in prostate cancer, Cancer Res, 72, 831, 10.1158/0008-5472.CAN-11-3110 · DOI
  20. Khazaie, 2011, The significant role of mast cells in cancer, Cancer Metastasis Rev, 30, 45, 10.1007/s10555-011-9286-z · DOI
  21. Maltby, 2009, Mast cells in tumor growth: Angiogenesis, tissue remodeling and immune-modulation, Biochim Biophys Acta, 1796, 19
  22. Krishnaswamy, 2001, The human mast cell: Functions in physiology and disease, Front Biosci, 6, D1109, 10.2741/krishnas · DOI
  23. Pittoni, 2011, Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers, Cancer Res, 71, 5987, 10.1158/0008-5472.CAN-11-1637 · DOI
  24. Taverna, 2013, Mast cells as a potential prognostic marker in prostate cancer, Dis Markers, 35, 711, 10.1155/2013/478303 · DOI
  25. Wasiuk, 2009, Mast cells as regulators of adaptive immunity to tumours, Clin Exp Immunol, 155, 140, 10.1111/j.1365-2249.2008.03840.x · DOI
  26. Nakai, 2007, The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate, Cancer Res, 67, 1378, 10.1158/0008-5472.CAN-06-1336 · DOI
  27. Sfanos, 2015, Bacterial prostatitis enhances 2-amino-1-methyl-6-phenylimidazo[4,5-β]pyridine (PhIP)-induced cancer at multiple sites, Cancer Prev Res, 8, 683, 10.1158/1940-6207.CAPR-15-0090 · DOI
  28. Fleischmann, 2009, Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis, Prostate, 69, 976, 10.1002/pros.20948 · DOI
  29. Globa, 2014, Mast cell phenotype in benign and malignant tumors of the prostate, Pol J Pathol, 65, 147, 10.5114/pjp.2014.43965 · DOI
  30. Sari, 1999, Mast cell variations in tumour tissue and with histopathological grading in specimens of prostatic adenocarcinoma, BJU Int, 84, 851, 10.1046/j.1464-410x.1999.00245.x · DOI
  31. Johansson, 2010, Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy, Am J Pathol, 177, 1031, 10.2353/ajpath.2010.100070 · DOI
  32. Nonomura, 2007, Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer, Br J Cancer, 97, 952, 10.1038/sj.bjc.6603962 · DOI
  33. Galli, 1993, The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others, Am J Pathol, 142, 965
  34. Payne, 2004, Mast cell tryptase: A review of its physiology and clinical significance, Anaesthesia, 59, 695, 10.1111/j.1365-2044.2004.03757.x · DOI
  35. Aydin, 2002, Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia, Pathol-Res Pract, 198, 267, 10.1078/0344-0338-00253 · DOI
  36. Chaux, 2012, Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer, Mod Pathol, 25, 1543, 10.1038/modpathol.2012.104 · DOI
  37. Cuka, 2014, PIP: An open source framework for multithreaded image analysis of whole slide images, Mod Pathol, 27, 398
  38. Schneider, 2012, NIH Image to ImageJ: 25 years of image analysis, Nat Methods, 9, 671, 10.1038/nmeth.2089 · DOI · Paper page
  39. Huang, 2008, SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment, Blood, 112, 1269, 10.1182/blood-2008-03-147033 · DOI
  40. Gurel, 2014, Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial, Cancer Epidemiol Biomarkers Prev, 23, 847, 10.1158/1055-9965.EPI-13-1126 · DOI

Cited by

Sorted by citations

See all 61

Metadata

Authors
Hempel, H. A., Cuka, N. S., Kulac, I., Barber, J. R., Cornish, T. C., Platz, E. A., De Marzo, A. M., & Sfanos, K. S.
Affiliations
  • Department of Pathology; Johns Hopkins University School of Medicine; Baltimore Maryland
  • Department of Epidemiology; Johns Hopkins Bloomberg School of Public Health; Baltimore Maryland
Venue
The Prostate
Publisher
Wiley
Published
2016-11-21
Volume
77
Issue
4
Pages
412-424
ISSN
0270-4137
DOI
10.1002/pros.23280
Cited by
61
References
1
Language
en
Licence
Funders
  • Department of Defense PCRP (W81XWH-12-1-0170; W81XWH-14-1-0364)
  • NIH/NCI Prostate SPORE Pathology Core (5P50CA058236)
  • Prostate Cancer Biorepository Network (PCBN) (W81XWH-10-2-0056, W81XWH-10-2-0046., 0056, W81XWH-10-2-0046)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence: Mast Cells and Prostate Cancer Recurrence. https://app.cochat.ai/papers/10.1002/pros.23280
The paper
Hempel, H. A., Cuka, N. S., Kulac, I., Barber, J. R., Cornish, T. C., Platz, E. A., De Marzo, A. M., & Sfanos, K. S. (2017). Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence: Mast Cells and Prostate Cancer Recurrence. The Prostate. https://doi.org/10.1002/pros.23280